- Home
- FRHC vs BMRN Comparison
FRHC vs BMRN Comparison
Compare FRHC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRHC | BMRN |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 12.3B |
| IPO Year | 1996 | 1999 |
Fundamental Metrics
Financial Performance| Metric | FRHC | BMRN |
|---|---|---|
| Price | $168.00 | $56.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 28 |
| Target Price | N/A | ★ $91.59 |
| AVG Volume (30 Days) | 77.4K | ★ 2.2M |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.29 | N/A |
| EPS | 0.52 | ★ 0.77 |
| Revenue | ★ $2,191,291,000.00 | $1,313,646,000.00 |
| Revenue This Year | N/A | $21.42 |
| Revenue Next Year | N/A | $14.51 |
| P/E Ratio | $331.78 | ★ $71.70 |
| Revenue Growth | 6.86 | ★ 17.62 |
| 52 Week Low | $107.98 | $49.26 |
| 52 Week High | $184.76 | $70.98 |
Technical Indicators
Market Signals| Indicator | FRHC | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 44.56 |
| Support Level | $163.09 | $53.89 |
| Resistance Level | $175.98 | $57.88 |
| Average True Range (ATR) | 5.55 | 1.58 |
| MACD | -0.57 | 0.29 |
| Stochastic Oscillator | 19.46 | 65.80 |
Price Performance
Historical ComparisonAbout FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.